Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors

This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors. The study estimates 5-year local control and prospectively characterizes acute and late treatment-related adverse events, quality of life, cardiopulmonary function, and patterns of failure. Photon therapy and proton therapy are both protocol-acceptable modalities and are selected by shared decision-making rather than randomization.

NCT Number	NCT07693855
Lead Sponsor	National Taiwan University Hospital Collaborators: National Taiwan University
Conditions	Thymus Neoplasms, Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma
Enrollment	69 participants
Start Date	2026-08-01
Primary Completion	2035-04-30 (estimated)
Study Completion	2035-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-16